- Home
- YALA vs OCS Comparison
YALA vs OCS Comparison
Compare YALA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | OCS |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United Arab Emirates | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.7M | 732.4M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YALA | OCS |
|---|---|---|
| Price | $5.52 | $12.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | ★ 329.8K | 170.1K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | $466.06 |
| Revenue Next Year | $7.13 | $479.73 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.01 | $10.52 |
| 52 Week High | $8.10 | $34.48 |
Technical Indicators
Market Signals| Indicator | YALA | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 41.38 |
| Support Level | $5.22 | $10.63 |
| Resistance Level | $5.67 | $13.28 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 63.64 | 12.29 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.